Multiple myeloma (MM) is a chronic hematologic malignancy that remains incurable, because most patients eventually relapse or become refractory to current treatments. MM is a major health problem, with a globally increasing incidence. While, increase in the choice of MM treatment, including new immunotherapies (bispecific monoclonal antibodies and chimeric antigen receptor (CAR)-T cell therapy), may allow to further improve MM patients’ outcomes, some non-therapy-related key issues may represent a pre-requisite towards improving MM outcomes in the next few years. This includes, the necessity of real-world evidence data, of a better definition of frailty, of a dynamic disease risk assessment, of a better definition of high-risk disease, broader accessibility to novel drugs, and to ensure diversity and representation of underrepresented groups. These key issues will be discussed in the current perspective review.
多发性骨髓瘤（MM）是一种慢性血液恶性肿瘤，目前仍无法治愈，因为大多数患者最终会复发或对现有治疗产生耐药性。MM是一个重大的健康问题，全球发病率持续上升。尽管MM治疗选择有所增加，包括新型免疫疗法（如双特异性单克隆抗体和嵌合抗原受体（CAR）-T细胞疗法），可能进一步提升MM患者的预后，但一些非治疗相关的关键问题可能是未来几年改善MM治疗结果的先决条件。这些问题包括：获取真实世界证据数据的必要性、更精准地定义虚弱状态、实施动态疾病风险评估、更明确高危疾病的定义、提高新药的可及性，以及确保代表性不足群体的多样性和代表性。这些关键议题将在当前的视角综述中予以探讨。
肿瘤(癌症)患者之家